Xenetic Biosciences, Inc.
XBIO
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 593.30K | 648.80K | 614.20K | 726.40K | 510.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 593.30K | 648.80K | 614.20K | 726.40K | 510.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 593.30K | 648.80K | 614.20K | 726.40K | 510.80K |
| SG&A Expenses | 656.60K | 705.70K | 745.70K | 1.13M | 834.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.54M | 1.75M | 1.11M | 2.06M | 1.78M |
| Operating Income | -942.40K | -1.10M | -499.50K | -1.34M | -1.27M |
| Income Before Tax | -903.10K | -1.05M | -436.70K | -1.27M | -1.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -903.10K | -1.05M | -436.70K | -1.27M | -1.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -903.10K | -1.05M | -436.70K | -1.27M | -1.20M |
| EBIT | -942.40K | -1.10M | -499.50K | -1.34M | -1.27M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 |
| Normalized Basic EPS | -0.37 | -0.43 | -0.18 | -0.52 | -0.48 |
| EPS Diluted | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 |
| Normalized Diluted EPS | -0.37 | -0.43 | -0.18 | -0.52 | -0.48 |
| Average Basic Shares Outstanding | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M |
| Average Diluted Shares Outstanding | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |